Abiopharma

🔍 Xia Yu (Director)

Company: Summit Therapeutics Inc. (SMMT)

Report Date: 2025-10-21

Detailed Transactions and Holdings:

• Acquired 533,617 shares of Common Stock at $18.74 per share (Direct)
  Date: 2025-10-21 | Code: P | equity_swap_involved: 0 | shares_owned_after: 32,057,147.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.
• F2: Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 25.96% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest.